Ropivacaine versus placebo on postoperative analgesia and chronic pain following third molar extraction: A Prospective Randomized Controlled Study - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Stomatology, Oral and Maxillofacial Surgery Année : 2020

Ropivacaine versus placebo on postoperative analgesia and chronic pain following third molar extraction: A Prospective Randomized Controlled Study

Résumé

Purpose: The present study aimed at assessing the efficiency of ropivacaine on post-operative pain for extraction of third molars.Methods: In a single centre, prospective, parallel, double blind randomised trial, patients scheduled for removal of all four third molars, ASA I-III patients<65 year-old patients were included. After intubation under general anesthesia (using intravenous remifentanil and propofol), for each of the third molars, 2mL of ropivacaine (7.5mg/mL) or placebo (0.9% saline solution) was injected into the vestibular capsule (total: 8mL) before extraction. At the end of surgery, similar analgesia was injected for both groups (intravenous paracetamol 1g and ketoprofene 100mg). The primary outcome was postoperative pain assessed by Visual Analog Scale (VAS). Postoperative consumption of analgesics (morphine titration in post-operative care unit when VAS>3/10, followed by oral tramadol 50mg after discharge), patient satisfaction, chronic pain (1-3 month), time in PACU and total hospitalization time were also recorded.Results: A total of 50 patients were analysed in each group with similar characteristics (ropivacaine vs. control, for age (years) 18 [17-21] vs. 18 [17-21], for sex (female) 33 (66%) vs. 25 (50%), and BMI (kg/m2): 20 [19-23] vs. 21 [19-23]). Area Under the Curve for VAS pain (0 to 4h) was lower for Ropivacaine group: 0.43 [0.19-0.66] vs. 0.63 [0.43-0.87], P=0.005. Use of morphine in PACU (8 vs. 18, P=0.02) and median length of stay in ambulatory setting (5 vs. 6h, P=0.03) were reduced in Ropivacaine vs. Placebo group. At days 1 and 4, VAS of pain was higher in Ropivacaine group (respectively 4 vs. 2, P=0.006 and 3 vs. 2, P=0.05). At month 1 and 3, pain and DN4 score were similar between groups, with a median VAS pain score at 0 for both groups (P=0.42). No difference was observed for patient satisfaction and adverse events.Conclusions: Ropivacaine provides an immediate efficient pain relief after extraction of third molars without benefit after discharge.Clinicaltrial registration: NCT01541059.
Fichier principal
Vignette du fichier
S2468785519301703.pdf (256.94 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02860822 , version 1 (22-08-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Hamadi Ghezal, Sophie Bouvet, Sarah Kabani, Jacques Ripart, Philippe Cuvillon. Ropivacaine versus placebo on postoperative analgesia and chronic pain following third molar extraction: A Prospective Randomized Controlled Study. Journal of Stomatology, Oral and Maxillofacial Surgery, 2020, 121 (2), pp.113-117. ⟨10.1016/j.jormas.2019.07.005⟩. ⟨hal-02860822⟩
20 Consultations
19 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More